Safety and Effectiveness of NicVAX in Treating Nicotine Dependent Individuals
A Phase 2 Study to Assess Safety and Immunogenicity of Five Doses of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) Administered to Smokers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Maastricht, Netherlands, 6229 HA
- University of Maastricht
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Current smoker
- Good general health, including mental health
- Alveolar carbon monoxide level greater than or equal to 10 ppm
Exclusion Criteria:
- Prior exposure to NicVAX
- Known allergy to any of the components of NicVAX
- Use of any smoking cessation aide
- Pregnant or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1
|
100 μg, Formulation A, on Days 0, 21, 42, 91 & 182
Other Names:
200 μg, Formulation A, on Days 0, 21, 42, 91 & 182
Other Names:
200 μg, Formulation B, on Days 0, 21, 42m 91 & 182
Other Names:
300 μg, Formulation B, on Days 0, 21, 42, 91 & 182
Other Names:
400 μg, Formulation B, on Days 0, 21, 42, 91 & 182
Other Names:
|
|
Experimental: 2
|
100 μg, Formulation A, on Days 0, 21, 42, 91 & 182
Other Names:
200 μg, Formulation A, on Days 0, 21, 42, 91 & 182
Other Names:
200 μg, Formulation B, on Days 0, 21, 42m 91 & 182
Other Names:
300 μg, Formulation B, on Days 0, 21, 42, 91 & 182
Other Names:
400 μg, Formulation B, on Days 0, 21, 42, 91 & 182
Other Names:
|
|
Experimental: 3
|
100 μg, Formulation A, on Days 0, 21, 42, 91 & 182
Other Names:
200 μg, Formulation A, on Days 0, 21, 42, 91 & 182
Other Names:
200 μg, Formulation B, on Days 0, 21, 42m 91 & 182
Other Names:
300 μg, Formulation B, on Days 0, 21, 42, 91 & 182
Other Names:
400 μg, Formulation B, on Days 0, 21, 42, 91 & 182
Other Names:
|
|
Experimental: 4
|
100 μg, Formulation A, on Days 0, 21, 42, 91 & 182
Other Names:
200 μg, Formulation A, on Days 0, 21, 42, 91 & 182
Other Names:
200 μg, Formulation B, on Days 0, 21, 42m 91 & 182
Other Names:
300 μg, Formulation B, on Days 0, 21, 42, 91 & 182
Other Names:
400 μg, Formulation B, on Days 0, 21, 42, 91 & 182
Other Names:
|
|
Experimental: 5
|
100 μg, Formulation A, on Days 0, 21, 42, 91 & 182
Other Names:
200 μg, Formulation A, on Days 0, 21, 42, 91 & 182
Other Names:
200 μg, Formulation B, on Days 0, 21, 42m 91 & 182
Other Names:
300 μg, Formulation B, on Days 0, 21, 42, 91 & 182
Other Names:
400 μg, Formulation B, on Days 0, 21, 42, 91 & 182
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Anti-nicotine Antibody concentrations
Time Frame: 19 time points from Day 0 to 365
|
19 time points from Day 0 to 365
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Smoking cessation
Time Frame: periods of 2 weeks, 4 weeks, or 12 weeks duration
|
periods of 2 weeks, 4 weeks, or 12 weeks duration
|
|
Fagerstrom Test for Nicotine Dependence
Time Frame: 7 time points from Day 0 to 365
|
7 time points from Day 0 to 365
|
|
Safety: vaccine reactogenicity
Time Frame: 7 days after each dose
|
7 days after each dose
|
|
Safety: adverse events
Time Frame: Day 0-365
|
Day 0-365
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Gary Horwith, Nabi Biopharmaceuticals
- Principal Investigator: Arjen De Vos, MD, PhD, Nabi Biopharmaceuticals
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NIDA-17894-2
- DPMC (Other Identifier: NIDA)
- Nabi-4505
- R01-17894-2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.